Sarepta (SRPT) Voting Questions Rekindle Hope, but RBC Still Expects a Negative Panel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
April 25, 2016 7:02 AM EDTSarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.
After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.
... More
Sarepta Therapeutics (SRPT) Active Ahead of Today's FDA AdCom and Expected Halt
April 25, 2016 6:40 AM EDTSarepta Therapeutics (NASDAQ: SRPT) is trading up ahead of today's FDA AdCom. After plunging Thursday on negative biased briefing documents, shares surged on Friday on positive draft questions. Shares may be halted shortly ahead of the panel.
... MoreBaird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking Move' by FDA
April 22, 2016 2:57 PM EDTBaird analyst Brian Skorney is incrementally positive on the FDA's move to include voting questions on Sarepta Therapeutic (NASDAQ: SRPT) eteplirsen.
The analyst called it a "shocking move.
"The final question will gauge panelists' read on the efficacy of the... More
FDA Draft Questions Changes Calculus on Sarepta (SRPT) Approval 'to Some Extent' - Janney Montgomery Scott
April 22, 2016 1:35 PM EDTJanney Montgomery Scott weighed in on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA released draft questions which re-ignited optimism for a positive outcome surrounding eteplirsen.
The analyst first notes there was not clear voting questions during BioMarin's drisapersen review.... More
Leerink Remains Skeptical Despite FDA Draft Questions on Sarepta (SRPT)
April 22, 2016 1:28 PM EDTLeerink Partners analyst Joseph Schwartz weighed in on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA released draft questions which re-ignited optimism for a positive outcome surrounding eteplirsen.
"Although voting question #7 could appear to imply a possible positive vote (and an... More
Sarepta Therapeutics (SRPT) Resumes Trading Following Volatility Spike
April 22, 2016 12:27 PM EDTSarepta Therapeutics (NASDAQ: SRPT) resumes trading after the volatility pause as FDA adds voting questions, which were viewed favorably. Shares last up 25%.
Sarepta Therapeutics (SRPT) triggers limit-up, limit-down trading pause
April 22, 2016 12:21 PM EDTSarepta Therapeutics (NASDAQ: SRPT) triggers limit-up, limit-down trading pause.
... MoreSarepta Therapeutics (SRPT) Continues Surge Higher as FDA Ads Voting Question
April 22, 2016 12:21 PM EDTSarepta Therapeutics (NASDAQ: SRPT) ads to gains. Chatter the FDA adding a voting question. Now up 30%
Sarepta Therapeutics (SRPT) Sees Strong Mid-Day Upside
April 22, 2016 12:03 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is seeing nice upside movement mid-day after getting slaughtered yesterday on the FDA briefing document. The AdCom is Monday 04/25. Shares last traded up 11% to $12.23.
... More